The Role of Atherogenic Lipoproteins in Cardiovascular Diseases

Dear Colleagues,

Cardiovascular disease (CVD) remains the leading cause of death worldwide, and reducing the levels of low-density lipoprotein cholesterol (LDL-C) is the main objective of CVD therapy and secondary prevention. While medications such as statins and Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) inhibitors have been successful at reducing LDL-C levels, it is important to note that excessively low levels of LDL-C can increase the risk of all-cause mortality. Lipoproteins play a vital role in lipid transportation and metabolism. In animals, the genetic knockdown of apolipoprotein B100 (apoB100) or apolipoprotein E (apoE) leads to the early onset of various diseases. 

For several decades, scientists have been studying modified lipoproteins such as oxidized LDL (oxLDL) and electronegative LDL (LDL(-)), as well as their signaling pathways. One of the most significant findings from this research is that these modified lipoproteins signal through the lectin-like oxidized LDL receptor-1 (LOX-1) to trigger vascular damage and the development of atherosclerosis. In this Special Issue, we present and discuss groundbreaking research on the high-throughput quantification of modified lipoproteins, in vivo evidence of atherosclerotic plaque formation, the pathogenesis of atherosclerosis, and innovative therapeutic strategies for tackling these modified lipoproteins.

Prof. Dr. Liang-Yin Ke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lysophosphatidylcholine (LPC)
• ceramide
• oxidized LDL (oxLDL)
• electronegative LDL (LDL(-))
• lectin-like oxidized LDL receptor-1 (LOX-1)
• lipid metabolism
• mitochondria dysfunction
• atherosclerosis
• cardiovascular diseases